Inhibrx Biosciences, Inc.: CEO Mark Lappe bought 10,040 shares

What happened Mark P. Lappe, CEO, purchased 10,040 shares of Inhibrx Biosciences common stock in multiple open market or private purchases on Oct 14, 2026, totaling $848,977. The filing lists these transactions:

• 2,470 shares at $84.07 for $207,655
• 2,470 shares at $85.00 for $209,948
• 100 shares at $85.76 for $8,576
• 2,449 shares at $84.07 for $205,889
• 2,451 shares at $85.00 for $208,333
• 100 shares at $85.76 for $8,576

Key details

• Transaction date: Oct 14, 2026; filing date: Oct 14, 2026 (filing date matches transaction date).
• Transaction code: P (purchase); described as "open market or private purchase" in the filing.
• Shares owned after the transactions: not reported in the filing.
• Footnotes in the filing:
  • F1: Purchases were made in multiple transactions at prices ranging from $83.61 to $84.59; reported price reflects weighted-average purchase price.
  • F3: Purchases were made in multiple transactions at prices ranging from $84.65 to $85.62; reported price reflects weighted-average purchase price.
  • F2: Some securities are directly owned by the Lappe Family Trust; Mark P. Lappe is a trustee and may be deemed to indirectly beneficially own those securities.
  • F4: Some securities are directly owned by a trust for the benefit of the reporting person's immediate family; Mark P. Lappe, as an immediate family member of the beneficiaries, may be deemed to indirectly beneficially own those securities.
• No late filing indication is shown in the information provided.

Why it may matter

• The filing reports open market or private purchases (code P). This filing does not show why the insider traded or why the company acted.